$GNLX
GENELUX Corp Stock $gnlx

$gnlx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018436 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue		$8.000K	$170.0K
YoY Change		-95.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.475M	$4.113M	$3.787M
YoY Change	0.94%	8.61%	245.84%
% of Gross Profit
Research & Development	$4.417M	$4.010M	$2.845M
YoY Change	50.08%	40.95%	20.09%
% of Gross Profit
Depreciation & Amortization	$38.00K	$84.00K	$136.0K
YoY Change	-71.85%	-38.24%	-1.45%
% of Gross Profit
Operating Expenses	$6.892M	$8.123M	$6.632M
YoY Change	27.75%	22.48%	91.45%
Operating Profit	-$6.892M	-$8.115M	-$6.462M
YoY Change	27.75%	25.58%	86.55%
Interest Expense	$316.0K	$265.0K	-$3.902M
YoY Change	-1416.67%	-106.79%	1057.86%
% of Operating Profit
Other Income/Expense, Net	$316.0K	$265.0K	-$3.902M
YoY Change	-174.18%	-106.79%	1057.86%
Pretax Income	-$6.576M	-$7.850M	-$10.36M
YoY Change	12.97%	-24.26%	172.67%
Income Tax
% Of Pretax Income
Net Earnings	-$6.576M	-$7.850M	-$10.36M
YoY Change	12.97%	-24.26%	172.67%
Net Earnings / Revenue		-98125.0%	-6096.47%
Basic Earnings Per Share	-$0.22	-$0.29	-$0.53
Diluted Earnings Per Share	-$0.22	-$0.29	-$0.53
COMMON SHARES
Basic Shares Outstanding	27.00M shares	26.87M shares	19.58M shares
Diluted Shares Outstanding	29.69M shares	26.85M shares	19.58M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.64M	$19.63M	$10.34M
YoY Change	23.94%	89.85%	44.08%
Cash & Equivalents	$7.858M	$4.061M	$10.34M
Short-Term Investments	$25.78M	$15.57M
Other Short-Term Assets	$1.234M	$1.577M	$1.718M
YoY Change	-20.03%	-8.21%	80.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.87M	$21.20M	$12.06M
YoY Change	21.57%	75.88%	48.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.306M	$1.116M	$617.0K
YoY Change	48.75%	80.88%	-68.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$6.813M
YoY Change
Other Assets	$92.00K	$92.00K	$92.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$10.31M	$3.472M	$2.560M
YoY Change	284.66%	35.63%	23.14%
TOTAL ASSETS
Total Short-Term Assets	$34.87M	$21.20M	$12.06M
Total Long-Term Assets	$10.31M	$3.472M	$2.560M
Total Assets	$45.18M	$24.68M	$14.62M
YoY Change	44.05%	68.83%	43.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.786M	$5.313M	$5.292M
YoY Change	6.74%	0.4%	18.42%
Accrued Expenses	$1.017M	$2.492M	$3.018M
YoY Change	-62.94%	-17.43%	-57.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$900.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due			$633.0K
YoY Change			-91.95%
Total Short-Term Liabilities	$5.803M	$7.805M	$10.54M
YoY Change	-26.34%	-25.97%	-64.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.382M
YoY Change	-100.0%	-100.0%	-92.01%
Other Long-Term Liabilities	$1.707M	$1.787M
YoY Change
Total Long-Term Liabilities	$1.707M	$1.787M	$1.382M
YoY Change	38.89%	29.31%	-92.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.803M	$7.805M	$10.54M
Total Long-Term Liabilities	$1.707M	$1.787M	$1.382M
Total Liabilities	$7.510M	$9.592M	$11.93M
YoY Change	-17.54%	-19.56%	-74.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$236.0M	-$229.4M	-$203.6M
YoY Change	12.67%	12.66%
Common Stock	$35.00K	$27.00K	$25.00K
YoY Change	34.62%	8.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$433.0K	$433.0K	$433.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$37.67M	$15.08M	$2.691M
YoY Change
Total Liabilities & Shareholders Equity	$45.18M	$24.68M	$14.62M
YoY Change	44.05%	68.83%	43.24%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$6.576M	-$7.850M	-$10.36M
YoY Change	12.97%	-24.26%	172.67%
Depreciation, Depletion And Amortization	$38.00K	$84.00K	$136.0K
YoY Change	-71.85%	-38.24%	-1.45%
Cash From Operating Activities	-$6.824M	-$4.354M	-$4.590M
YoY Change	25.95%	-5.14%	-262.48%
INVESTING ACTIVITIES
Capital Expenditures	$228.0K	$30.00K	$109.0K
YoY Change	-42.42%	-72.48%	626.67%
Acquisitions
YoY Change
Other Investing Activities	-$16.88M	-$1.661M
YoY Change
Cash From Investing Activities	-$17.11M	-$1.691M	-$109.0K
YoY Change	4219.7%	1451.38%	626.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	27.73M	$688.0K	$14.64M
YoY Change	22.6%	-95.3%	-11361.54%
NET CHANGE
Cash From Operating Activities	-6.824M	-$4.354M	-$4.590M
Cash From Investing Activities	-17.11M	-$1.691M	-$109.0K
Cash From Financing Activities	27.73M	$688.0K	$14.64M
Net Change In Cash	3.797M	-$5.357M	$9.941M
YoY Change	-77.4%	-153.89%	270.93%
FREE CASH FLOW
Cash From Operating Activities	-$6.824M	-$4.354M	-$4.590M
Capital Expenditures	$228.0K	$30.00K	$109.0K
Free Cash Flow	-$7.052M	-$4.384M	-$4.699M
YoY Change	21.29%	-6.7%	-267.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001231457
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization		usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q1	GNLX	Issuance Of Common Shares Upon Conversion Of Preferred Stock Dividends Payable IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024Q1	GNLX	Fair Value Of Warrants With Conversion Of Convertible Notes Payable FairValueOfWarrantsWithConversionOfConvertibleNotesPayable		usd
CY2024Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2024Q1	GNLX	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	GNLX	Extension Of Rightofuse Asset And Operating Lease ExtensionOfRightofuseAssetAndOperatingLease		usd
CY2024Q1	GNLX	Reclassification Of Deferred Offering Costs To Shareholders Equity ReclassificationOfDeferredOfferingCostsToShareholdersEquity		usd
CY2024Q1	GNLX	Reclassification Of Warrant Liabilities To Shareholders Equity ReclassificationOfWarrantLiabilitiesToShareholdersEquity		usd
CY2024Q1	GNLX	Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees To Shareholders Equity ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity		usd
CY2024Q1	GNLX	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2024Q1	GNLX	Conversion Of Dividends Payable To Shareholders Equity ConversionOfDividendsPayableToShareholdersEquity		usd
CY2024Q1	GNLX	Conversion Of Notes Payableshareholders And Accrued Interest To Shareholders Equity ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity		usd
CY2023Q1	GNLX	Conversion Of Notes Payableshareholders And Accrued Interest To Shareholders Equity ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity		usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodTotalFairValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Cancelled SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceCancelled
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Exercised SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceExercised
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q1	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Expired SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceExpired
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	GENELUX CORPORATION
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41599
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0583529
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2625 Townsgate Road
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 230
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
CY2024Q1	dei	City Area Code CityAreaCode	(805)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	267-9889
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	3472000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3690000	usd
CY2024Q1	us-gaap	Assets Assets	24676000	usd
CY2023Q4	us-gaap	Assets Assets	27893000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5313000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3784000	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1908000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2117000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	584000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	653000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7805000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6554000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1787000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1866000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	9592000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8420000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26996740	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26996740	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26788986	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26788986	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	433333	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	433333	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	433000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	433000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	244869000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241389000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-229374000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221524000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	15084000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19473000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24676000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27893000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	170000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4010000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2845000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4113000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3787000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	8123000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	6632000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8115000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6462000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	265000	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	143000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	649000	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3110000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	265000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3902000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7850000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10364000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26849737	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26849737	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19575631	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19575631	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7850000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10364000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7869000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10364000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-35783000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	227000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12632000	usd
CY2023Q1	GNLX	Issuance Of Common Shares Upon Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees	29896000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	198000	usd
CY2023Q1	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing	2606000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	169000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3110000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10364000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2691000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19473000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19473000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1489000	usd
CY2024Q1	GNLX	Unrealized Gain On Shortterm Investments UnrealizedGainOnShorttermInvestments	-19000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	989000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	688000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7850000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7850000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	15084000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	15084000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7850000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10364000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	84000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	136000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	151000	usd
CY2024Q1	GNLX	Rightofuse Asset RightofuseAsset	164000	usd
CY2023Q1	GNLX	Rightofuse Asset RightofuseAsset	118000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	649000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1489000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	227000	usd
CY2024Q1	GNLX	Fair Value Of Restricted Stock Units FairValueOfRestrictedStockUnits	989000	usd
CY2023Q1	GNLX	Fair Value Of Restricted Stock Units FairValueOfRestrictedStockUnits	198000	usd
CY2024Q1	GNLX	Cost Of Stock Option Modifications Repricing CostOfStockOptionModificationsRepricing	-314000	usd
CY2023Q1	GNLX	Cost Of Stock Option Modifications Repricing CostOfStockOptionModificationsRepricing	-2606000	usd
CY2023Q1	GNLX	Fair Value Of Warrants With Conversion Of Convertible Notes Payable FairValueOfWarrantsWithConversionOfConvertibleNotesPayable	3110000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	565000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	223000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1529000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-913000	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-209000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	58000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	92000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-170000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-148000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-114000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4354000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4590000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3161000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	1500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1691000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-109000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	900000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	460000	usd
CY2023Q1	GNLX	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	303000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	688000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14503000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	688000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14640000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5357000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9941000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9418000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	397000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4061000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10338000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	50000	usd
CY2023Q1	GNLX	Extension Of Rightofuse Asset And Operating Lease ExtensionOfRightofuseAssetAndOperatingLease	649000	usd
CY2023Q1	GNLX	Reclassification Of Deferred Offering Costs To Shareholders Equity ReclassificationOfDeferredOfferingCostsToShareholdersEquity	1871000	usd
CY2023Q1	GNLX	Reclassification Of Warrant Liabilities To Shareholders Equity ReclassificationOfWarrantLiabilitiesToShareholdersEquity	169000	usd
CY2023Q1	GNLX	Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees To Shareholders Equity ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity	29896000	usd
CY2023Q1	GNLX	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	22000	usd
CY2023Q1	GNLX	Conversion Of Dividends Payable To Shareholders Equity ConversionOfDividendsPayableToShareholdersEquity	3443000	usd
CY2024Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_809_eus-gaap--BasisOfAccounting_zfbNzk7nFa8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82E_zN5TrIMoUmqg">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization and Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genelux Corporation (“Genelux” or the “Company”), a Delaware Corporation, incorporated on September 4, 2001, is a late clinical-stage biopharmaceutical company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic solutions for cancer for which there is no effective treatment today. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation of Unaudited Financial Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, the Company has experienced recurring losses from operations since inception and incurred a net loss of $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20240101__20240331_zV0Whp9oDW27" title="Net loss">7,850</span> and used cash in operations of $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240331_zL3J7fRv36Zd" title="Cash used in operations">4,354</span> during the three months ended March 31, 2024, and had an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240331_zLYNvgGTLOze" title="Accumulated deficit">229,374</span> as of March 31, 2024. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2024, the Company had cash and cash equivalents, and short-term investments, in the amount of $<span id="xdx_90B_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_c20240331_z2xMWC0bZozl" title="Cash and cash equivalents and short-term investments">19,627</span>. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through equity and debt financings, and licensing income, and it expects to continue to rely on these sources of capital in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing, or grant unfavorable terms in future licensing agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7850000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4354000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-229374000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	19627000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z5ODSrQL4Tn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zj5xcSHk3Jf7">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5574218	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5419391	shares
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	18554000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15573000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	7000	usd
CY2024Q1	us-gaap	Debt Securities Trading And Available For Sale DebtSecuritiesTradingAndAvailableForSale	15566000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4649000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4619000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3533000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3449000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1170000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	84000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	136000	usd
CY2023Q4	GNLX	Facility Design Services FacilityDesignServices	995000	usd
CY2024Q1	GNLX	Additional Design Services AdditionalDesignServices	3000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2117000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	321000	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	321000	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1908000	usd
CY2018Q3	us-gaap	Payments For Rent PaymentsForRent	10000	usd
CY2018Q3	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend for an additional five years
CY2018Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2022Q2	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	the option to extend the lease for an additional five years
CY2018Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	174000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	860000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	686000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended the lease for an additional two-year period, through October 2030, with no changes to any of the other terms of the lease and has the option to extend the lease for an additional five years. Prior to the extension through October 2030, the remaining lease liability amounted to $701
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	909000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0700	pure
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	208000	usd
CY2020Q4	us-gaap	Payments For Rent PaymentsForRent	18000	usd
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2023Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended the lease through December 2024, with no changes to any of the other terms of the lease.
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	30000	usd
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	649000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.055	pure
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	637000	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	10000	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	656000	usd
CY2021Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2023Q4	us-gaap	Payments For Rent PaymentsForRent	12000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extend for an additional five years
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	803000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0700	pure
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	148000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	114000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2371000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2519000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	164000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	118000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2264000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2428000	usd
CY2024Q1	GNLX	Rent Expense RentExpense	9000	usd
CY2023Q1	GNLX	Rent Expense RentExpense	9000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26996740	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26996740	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26788986	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26788986	shares
CY2023Q4	GNLX	Additional Commitments Received AdditionalCommitmentsReceived	24000000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	57900	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested In Period Total Fair Value Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedInPeriodTotalFairValueBeginning	1103000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.40
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	130690	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue	852000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.52
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	131267	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	989000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	7.53
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	57323	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Non Options Vested In Period Total Fair Value Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodTotalFairValueEnding	966000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	16.85
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	989000	usd
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested In Period Total Fair Value Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedInPeriodTotalFairValueEnding	966000	usd
CY2024Q1	GNLX	Fair Market Value Of Shares Percentage Description FairMarketValueOfSharesPercentageDescription	(i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company.
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5118920	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.76
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5118920	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.76
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3855160	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.09
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1263760	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	20.91
CY2024Q1	GNLX	Cost Of Stock Option Modifications CostOfStockOptionModifications	-303000	usd
CY2024Q1	GNLX	Repricing Costs RepricingCosts	2733000	usd
CY2023	GNLX	Repricing Costs RepricingCosts	2689000	usd
CY2024Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	11000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1489000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18090000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1645000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	512759	shares
CY2023Q4	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	7.14
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	76487	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice	9.00
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	38297	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice	9.15
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	397975	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	6.59
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	397975	shares
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	6.59
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	76487	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.00
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	688000	usd
CY2024Q1	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	457000	usd

Files In Submission

Name	View Source	Status
0001493152-24-018436-index-headers.html	Edgar Link	pending
0001493152-24-018436-index.html	Edgar Link	pending
0001493152-24-018436.txt	Edgar Link	pending
0001493152-24-018436-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
gnlx-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gnlx-20240331_cal.xml	Edgar Link	unprocessable
gnlx-20240331_def.xml	Edgar Link	unprocessable
gnlx-20240331_lab.xml	Edgar Link	unprocessable
gnlx-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GNLX
GENELUX Corp Stock $gnlx

2024 Q2 Form 10-Q Financial Statement

#000149315224018436 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNLX GENELUX Corp Stock $gnlx

2024 Q2 Form 10-Q Financial Statement

#000149315224018436 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNLX
GENELUX Corp Stock $gnlx